Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.
2.

Uricosuric medications for chronic gout.

Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C.

Cochrane Database Syst Rev. 2014 Nov 14;(11):CD010457. doi: 10.1002/14651858.CD010457.pub2.

PMID:
25392987
3.

Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL.

Clin Rheumatol. 2007 Sep;26(9):1459-65.

PMID:
17308859
4.

Allopurinol for chronic gout.

Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ.

Cochrane Database Syst Rev. 2014 Oct 14;(10):CD006077. doi: 10.1002/14651858.CD006077.pub3. Review.

PMID:
25314636
5.

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, GarcĂ­a-Erauskin G, Ruiz-Lucea E.

Ann Rheum Dis. 1998 Sep;57(9):545-9.

6.

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.

Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR.

Ann Rheum Dis. 2009 Jun;68(6):892-7. doi: 10.1136/ard.2008.091462.

PMID:
18633127
7.

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR.

Ann Rheum Dis. 2009 Jan;68(1):51-6. doi: 10.1136/ard.2007.083071.

PMID:
18250112
8.

Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.

Kydd AS, Seth R, Buchbinder R, Falzon L, Edwards CJ, van der Heijde DM, Bombardier C.

J Rheumatol Suppl. 2014 Sep;92:33-41. doi: 10.3899/jrheum.140460. Review.

PMID:
25180126
9.
10.

[Life-threatening adverse effects of pharmacologic antihyperuricemic therapy].

Russmann S, Lauterburg B.

Ther Umsch. 2004 Sep;61(9):575-7. German.

PMID:
15493119
11.

Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.

Ahn SO, Ohtomo S, Kiyokawa J, Nakagawa T, Yamane M, Lee KJ, Kim KH, Kim BH, Tanaka J, Kawabe Y, Horiba N.

J Pharmacol Exp Ther. 2016 Apr;357(1):157-66. doi: 10.1124/jpet.115.231647.

PMID:
26907620
12.

Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"?

Jansen TL, Reinders MK, van Roon EN, Brouwers JR.

Clin Exp Rheumatol. 2004 Sep-Oct;22(5):651. No abstract available.

PMID:
15485024
13.

Gout in solid organ transplantation: a challenging clinical problem.

Stamp L, Searle M, O'Donnell J, Chapman P.

Drugs. 2005;65(18):2593-611. Review.

PMID:
16392875
14.

Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today?

Gravatt L.

N Z Med J. 2013 Sep 13;126(1382):118-9. No abstract available.

PMID:
24154779
15.

Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

Heel RC, Brogden RN, Speight TM, Avery GS.

Drugs. 1977 Nov;14(5):349-66. Review.

PMID:
338280
16.

Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone.

Roberts RL, Wallace MC, Wright DF, Cadzow M, Dalbeth N, Jones PB, Stamp LK, Harrison AA, Black MA, Merriman TR.

Joint Bone Spine. 2014 Mar;81(2):160-3. doi: 10.1016/j.jbspin.2013.07.006.

PMID:
23932726
17.

Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.

[No authors listed]

Prescrire Int. 2009 Apr;18(100):63-5.

PMID:
19585722
18.

Pegloticase. An excessively dangerous and inadequately evaluated hypouricaemic drug.

[No authors listed]

Prescrire Int. 2014 Jul;23(151):173-6.

PMID:
25162087
19.

The challenges of gout management in the elderly.

Stamp LK, Jordan S.

Drugs Aging. 2011 Aug 1;28(8):591-603. doi: 10.2165/11592750-000000000-00000. Review.

PMID:
21812496
20.

Influence of urate-lowering therapies on renal handling of uric acid.

Ma L, Wei L, Chen H, Zhang Z, Yu Q, Ji Z, Jiang L.

Clin Rheumatol. 2016 Jan;35(1):133-41. doi: 10.1007/s10067-014-2806-9.

PMID:
25373449
Items per page

Supplemental Content

Support Center